Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

Launched by CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD. ·

Keywords

ClinConnect Summary

This clinical trial is studying whether adding a medicine called Nanocrystalline Megestrol Acetate to the usual cancer treatment can help patients with locally advanced non-small cell lung cancer. Specifically, the researchers want to see if this medicine can improve appetite and help patients maintain or gain weight while they receive chemoradiotherapy—a combination of chemotherapy and radiation therapy given at the same time.

The trial is open to adults of all genders who have this type of lung cancer and have not yet received any systemic treatment (treatments that affect the whole body, like chemotherapy). Participants will be randomly assigned to receive either the Nanocrystalline Megestrol Acetate along with their standard cancer treatment or a placebo (a pill with no active medicine) with standard treatment. Throughout the study, patients will be monitored to check how well they maintain their appetite and weight, as well as to track any side effects. This study is currently recruiting participants and aims to find safer and more effective ways to support patients during their cancer treatment.

Gender

ALL

Eligibility criteria